Computerised-hepatitis B-model is subject to processing axiom: Garbage in, garbage out [3]

Journal of Hepatology

Volumn 39, Issue 1, 2003, Pages 133-134

  Tiwari, Lokesh ^a   Varghese, Raji Mathew ^a   Puliyel, Jacob M ^a  

^a ST STEPHEN S HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER PROGRAM; COMPUTER SIMULATION; DISEASE CARRIER; DISEASE COURSE; DISEASE MODEL; HEPATITIS B; HUMAN; INDIA; LETTER; LIVER CIRRHOSIS; MATHEMATICAL COMPUTING; MORTALITY; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL; SURVIVAL;

EID: 0038649726     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00174-0     Document Type: Letter

References (15)

1. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003;38:215-22.
2. Miller MA, Kane M. Routine hepatitis B immunization in India: cost effectiveness assessment. Indian J Pediatr 2000;67:299-300.
3. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral hepatitis and liver disease. Orlando, FL: Grune and Stratton; 1984. p. 209-24.
4. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
5. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863-73.
6. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alfa2b for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
7. Louis-Jacques O, Olson AD. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. J Pediatr Gastroenterol Nutr 1997;24:25-32.
8. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type B: the EUROHEP Study Group on hepatitis B virus and cirrhosis. Hepatology 1995;21:77-84.
9. DeJongh FE, Janssen HLA, DeMan RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
10. D'Amico G, Marabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1985;31:468-75.
11. Liaw Y-F, Lin D-Y, Chen T-J, Chu C-M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235-41.
12. Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India III. Liver. Indian J Gastroenterol 1998;17:100-3.
13. McMohan BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
14. Ojha RK, Abraham J, Khosla M, Puliyel JM. Vaccine promotion is circumventing market forces. Br Med J 2002;324:975.
15. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, et al. A long term follow up study of asymptomatic hepatitis B surface antigen positive carriers in Montreal. Gastroenterology 1994;106:1000-5.